Direkt zum Inhalt
Merck
  • Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation.

Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation.

PloS one (2014-07-23)
Daniël B van Schalkwijk, Wilrike J Pasman, Henk F J Hendriks, Elwin R Verheij, Carina M Rubingh, Kees van Bochove, Wouter H J Vaes, Martin Adiels, Andreas P Freidig, Albert A de Graaf
ZUSAMMENFASSUNG

Dietary medium chain fatty acids (MCFA) and linoleic acid follow different metabolic routes, and linoleic acid activates PPAR receptors. Both these mechanisms may modify lipoprotein and fatty acid metabolism after dietary intervention. Our objective was to investigate how dietary MCFA and linoleic acid supplementation and body fat distribution affect the fasting lipoprotein subclass profile, lipoprotein kinetics, and postprandial fatty acid kinetics. In a randomized double blind cross-over trial, 12 male subjects (age 51±7 years; BMI 28.5±0.8 kg/m2), were divided into 2 groups according to waist-hip ratio. They were supplemented with 60 grams/day MCFA (mainly C8:0, C10:0) or linoleic acid for three weeks, with a wash-out period of six weeks in between. Lipoprotein subclasses were measured using HPLC. Lipoprotein and fatty acid metabolism were studied using a combination of several stable isotope tracers. Lipoprotein and tracer data were analyzed using computational modeling. Lipoprotein subclass concentrations in the VLDL and LDL range were significantly higher after MCFA than after linoleic acid intervention. In addition, LDL subclass concentrations were higher in lower body obese individuals. Differences in VLDL metabolism were found to occur in lipoprotein lipolysis and uptake, not production; MCFAs were elongated intensively, in contrast to linoleic acid. Dietary MCFA supplementation led to a less favorable lipoprotein profile than linoleic acid supplementation. These differences were not due to elevated VLDL production, but rather to lower lipolysis and uptake rates.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Acetonitril, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
Acetonitril, HPLC Plus, ≥99.9%
Sigma-Aldrich
Ameisensäure, reagent grade, ≥95%
Sigma-Aldrich
Acetonitril, ACS reagent, ≥99.5%
Sigma-Aldrich
Ameisensäure, ACS reagent, ≥96%
Sigma-Aldrich
Acetonitril, anhydrous, 99.8%
Sigma-Aldrich
Acetonitril, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
Ameisensäure, ACS reagent, ≥88%
Sigma-Aldrich
Octansäure, ≥99%
Sigma-Aldrich
Acetonitril, biotech. grade, ≥99.93%
Sigma-Aldrich
Acetonitril, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
Octansäure, ≥98%
Sigma-Aldrich
Ameisensäure, ≥95%, FCC, FG
Sigma-Aldrich
Acetonitril, suitable for DNA synthesis, ≥99.9% (GC)
Supelco
Acetonitril (unverdünnt), Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Acetonitril, analytical standard
Sigma-Aldrich
Octansäure, ≥98%, FG
Sigma-Aldrich
Octansäure, natural, ≥98%, FG
Sigma-Aldrich
Acetonitril, ReagentPlus®, 99%
Supelco
Octansäure, analytical standard
Supelco
Caprylsäure (Octansäure), Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ameisensäure -Lösung, BioUltra, 1.0 M in H2O
Leucin, European Pharmacopoeia (EP) Reference Standard
Caprylsäure, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
DL-Leucin, ≥99% (HPLC)
USP
Lösungsmittelrückstände Klasse 2 - Acetonitril, United States Pharmacopeia (USP) Reference Standard
Supelco
Acetonitril, Pharmaceutical Secondary Standard; Certified Reference Material